Market closed
Spero Therapeutics/$SPRO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Spero Therapeutics
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Ticker
$SPRO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
32
ISIN
US84833T1034
Website
SPRO Metrics
BasicAdvanced
$35M
-
-$1.27
0.69
-
Price and volume
Market cap
$35M
Beta
0.69
52-week high
$1.72
52-week low
$0.51
Average daily volume
156K
Financial strength
Current ratio
2.186
Quick ratio
2.147
Long term debt to equity
5.531
Total debt to equity
9.316
Management effectiveness
Return on assets (TTM)
-30.93%
Return on equity (TTM)
-89.62%
Valuation
Price to revenue (TTM)
0.698
Price to book
0.73
Price to tangible book (TTM)
0.73
Price to free cash flow (TTM)
-1.429
Growth
Revenue change (TTM)
-53.77%
Earnings per share change (TTM)
-395.35%
3-year revenue growth (CAGR)
38.00%
3-year earnings per share growth (CAGR)
-24.11%
What the Analysts think about SPRO
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Spero Therapeutics stock.
SPRO Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
SPRO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
SPRO News
AllArticlesVideos
Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer
GlobeNewsWire·2 weeks ago
Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Spero Therapeutics stock?
Spero Therapeutics (SPRO) has a market cap of $35M as of May 13, 2025.
What is the P/E ratio for Spero Therapeutics stock?
The price to earnings (P/E) ratio for Spero Therapeutics (SPRO) stock is 0 as of May 13, 2025.
Does Spero Therapeutics stock pay dividends?
No, Spero Therapeutics (SPRO) stock does not pay dividends to its shareholders as of May 13, 2025.
When is the next Spero Therapeutics dividend payment date?
Spero Therapeutics (SPRO) stock does not pay dividends to its shareholders.
What is the beta indicator for Spero Therapeutics?
Spero Therapeutics (SPRO) has a beta rating of 0.69. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.